3Escorsell A, Bandi JC, Moitinho E, et al. Time profile of th ehaemodynamic effects of terlipressin in portal hypertension[J]. J Hepatol,1997,26(3) :621-627.
4Romero G, Kravetz D, Argonz J, et al. Terlipressin is more effective-indecreasing variceal pressure than portal pressure in cirrhotic patients [J]. J Hepatol, 2000,32(3) :419-425.
5Moiler S, Hansen EF, Becker U, et al. Central and systemic haemodynamic effects of terlipressin in portal hypertensive patients [J]. Liver, 2000,20(1) :51-59.
7Sieber CC, Lee FY, Groszmann RJ. Long-term octreotide treatment prevents vascular hyporeactivity in portalhypertensive rats [J]. Hepatology, 1996,23(5) : 1218-1223.
8Corley DA, Cello JP, Adkisson W, et al. Kerlikowske K.Oetreotide foraeute esophageal varieeal bleeding: a metaanalysis [J]. Gastroenterology, 2001,120(4) :946-9S4.
9Morabito A, Pagliaro L. Second study shows that octrcotide may prevent early rebleeding in cirrhosis [J]. BMJ, 1998,316(7140) : 1320.
10DAmico G, Politi F, DAntoni A, et al. Effects of long-term administration of octreotide in portal vein-stenosed rats [J].Hepatology, 1996,23(3) :537-543.
4BAYRAKTAR Y,BALKANCI F,UZUNALIMOGLU B,et al.Isportal hypertension due to liver cirrhosis a major factor in thedevelopment of portal hypertensive gastropathy? [ J].Am JGastroenterol,1996,91(3):554-558.
